• Citius Oncology posted fiscal Q2 net loss of $26.6 million, widening from $7.7 million year-earlier; net product revenues rose to $1.7 million from no revenue.
• G&A expenses climbed to $23.6 million from $2.2 million, driven by a $19.7 million one-time CMO contract cancellation charge.
• Gross profit came in at $1.3 million, implying an 80% margin; cash and cash equivalents totaled $2.6 million at quarter end.
• Subsequent to quarter end, up to $36.5 million in debt and equity capital was secured, including $11.5 million in warrant exercise proceeds plus a $25 million senior secured term loan facility with $10 million funded at close.
• LYMPHIR launch metrics showed 83% of target accounts on formulary or in review, near 100% coverage of covered commercial lives with no reimbursement denials; management expects full U.S. commercial team deployment by mid-summer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Citius Oncology Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY61123) on May 15, 2026, and is solely responsible for the information contained therein.